An Arkansas bill passed today that aims to create a fairer pharmaceutical business market by restricting the abilities of pharmacy benefit managers.

Several rapid diagnostic tests are commercially available and many in-house assays have been developed but the performance characteristics of many of these tests have not been adequately evaluated.